LALPATHLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | LALPATHLAB | Market Cap | 22,908 Cr. | Current Price | 1,367 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 43.1 | Book Value | 148 ₹ | Dividend Yield | 0.88 % | ROCE | 29.4 % |
| ROE | 23.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,393 ₹ | DMA 200 | 1,443 ₹ |
| Chg in FII Hold | -3.11 % | Chg in DII Hold | 2.17 % | PAT Qtr | 141 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 44.7 | MACD | 9.36 | Volume | 3,01,935 | Avg Vol 1Wk | 2,27,566 |
| Low price | 1,272 ₹ | High price | 1,771 ₹ | PEG Ratio | 1.94 | Debt to equity | 0.08 |
| 52w Index | 19.1 % | Qtr Profit Var | -4.92 % | EPS | 30.3 ₹ | Industry PE | 34.6 |
📊 LALPATHLAB is trading slightly below both its 50 DMA (1,393 ₹) and 200 DMA (1,443 ₹), indicating medium-term weakness. RSI at 44.7 suggests neutral-to-bearish momentum, while MACD at 9.36 shows mild positive divergence. Current volume (3,01,935) is above average (2,27,566), reflecting strong participation. Bollinger Bands place price near the lower mid-range, pointing to consolidation with mild bearish undertones.
🎯 Entry Zone: 1,340 ₹ – 1,360 ₹ (support near 1,350 ₹)
💰 Exit Zone: 1,400 ₹ – 1,430 ₹ (resistance near 200 DMA)
🔄 Trend Status: Consolidating with mild bearish bias; reversal requires sustained breakout above 1,443 ₹.
Positive
- Strong ROE (23.1%) and ROCE (29.4%) highlight excellent efficiency.
- EPS of 30.3 ₹ supports valuation consistency.
- Low debt-to-equity ratio (0.08) ensures financial stability.
- DII holdings increased (+2.17%), reflecting strong domestic institutional support.
Limitation
- Trading below both 50 DMA and 200 DMA indicates technical weakness.
- High P/E (43.1) compared to industry PE (34.6) suggests overvaluation.
- PEG ratio (1.94) reflects stretched growth expectations.
- Quarterly profit variation (-4.92%) highlights earnings pressure.
Company Negative News
- Decline in FII holdings (-3.11%) signals reduced foreign investor confidence.
- Sequential PAT decline (141 Cr → 113 Cr) highlights earnings weakness.
Company Positive News
- Quarterly profit resilience (+24% sequential growth) despite overall decline.
- DII inflows (+2.17%) show confidence in near-term performance.
Industry
- Industry PE at 34.6 is lower than LALPATHLAB’s 43.1, highlighting premium valuation.
- Diagnostics and healthcare sector remains resilient with long-term demand growth.
Conclusion
⚖️ LALPATHLAB is consolidating with mild bearish signals but supported by strong fundamentals and domestic institutional inflows. Entry near 1,340–1,360 ₹ with exits around 1,400–1,430 ₹ is favorable for swing trades. Long-term investors should be cautious due to high valuations and weak earnings momentum despite strong efficiency ratios.
This is the short-term technical trade view. I can also prepare a sector overlay benchmarking LALPATHLAB against other diagnostic peers (like Metropolis or Thyrocare) to refine entry/exit strategies for your workflow reports.